Surf Taiwan News, Browse the World »
New drugs may make a dent in lung, ovarian cancer
Studies show promise for new drugs in lung, leukemia, ovarian cancers; some raise cost concern
By MARILYNN MARCHIONE
Associated Press
2014-05-31 11:42 PM

CHICAGO (AP) -- For the first time in a decade, an experimental drug has extended the life of patients with advanced lung cancer who relapsed after standard chemotherapy.

But the benefit in the study was so small -- six extra weeks, on average -- that it is raising fresh questions about the value of some costly new cancer medicines.

Eli Lilly and Co.'s drug Cyramza (sih-RAM-zuh) was tested in more than 1,200 patients. It is sold now for stomach cancer and costs $6,000 per infusion.

The study was discussed Saturday at a cancer conference in Chicago where doctors also reported progress with new drugs against relapsed ovarian cancer and chronic lymphocytic leukemia, the most common type of leukemia in adults.

Advertisement »
HOME |  WORLD |  Politics |  Business |  Sports |  Lifestyle |  TAIWAN |  Technology |  Health |  SUPPLEMENT |  Society |  OPINION
  • Taiwan News  ©  2014 All Rights Reserved.